FR1550956A - - Google Patents

Info

Publication number
FR1550956A
FR1550956A FR1550956DA FR1550956A FR 1550956 A FR1550956 A FR 1550956A FR 1550956D A FR1550956D A FR 1550956DA FR 1550956 A FR1550956 A FR 1550956A
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Application granted granted Critical
Publication of FR1550956A publication Critical patent/FR1550956A/fr
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Fodder In General (AREA)
FR1550956D 1964-07-20 1965-07-20 Expired FR1550956A (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US383910A US3320124A (en) 1964-07-20 1964-07-20 Method for treating coccidiosis with quinazolinones

Publications (1)

Publication Number Publication Date
FR1550956A true FR1550956A (enExample) 1968-12-27

Family

ID=23515259

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1550956D Expired FR1550956A (enExample) 1964-07-20 1965-07-20

Country Status (7)

Country Link
US (1) US3320124A (enExample)
BR (1) BR6571429D0 (enExample)
DE (1) DE1545551B2 (enExample)
ES (1) ES315612A1 (enExample)
FR (1) FR1550956A (enExample)
GB (1) GB1087015A (enExample)
IL (1) IL23717A (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2703652A1 (de) * 1976-01-29 1977-08-04 Roussel Uclaf Neues chinazolinon und dessen salze, deren herstellungsverfahren und diese enthaltende pharmazeutische zusammensetzungen
EP0027768A1 (fr) * 1979-10-23 1981-04-29 Roussel-Uclaf Nouvelles résines échangeuses d'ions du type acide, leur préparation, leur application comme médicaments et les compositions les renfermant
FR2467630A1 (fr) * 1979-10-23 1981-04-30 Roussel Uclaf Nouvelles resines echangeuses d'ions du type acide, leur procede de preparation et leur application comme medicament
FR2468368A1 (fr) * 1979-08-23 1981-05-08 Hoechst Ag Agent pour le traitement de theilerioses a base de quinazolinone
EP0794780A4 (en) * 1994-12-22 1997-11-12 Davidson M Clifford PHARMACEUTICAL COMPOSITIONS CONTAINING QUINAZOLINONE AND METHODS OF USE THEREOF

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797486A (en) * 1986-09-08 1989-01-10 Pfizer Inc. Heterocyclic ring fused pyrimidine-4(3H)-ones as anticoccidial agents
US4725599A (en) * 1986-09-08 1988-02-16 Pfizer Inc. Heterocyclic ring fused pyrimidine-4 (3H)-ones as anticoccidial agents
US5314700A (en) * 1991-01-28 1994-05-24 Ethyl Corporation Poultry feed component
CA2113229C (en) * 1994-01-11 1999-04-20 Mark Pines Anti-fibrotic quinazolinone-containing compositions and methods for the use thereof
IL110831A (en) * 1994-08-31 1998-12-27 Hadasit Med Res Service Pharmaceutical compositions containing quinazolinone derivatives for preventing restenosis
US6090814A (en) * 1995-08-15 2000-07-18 Agricultural Research Organization Ministry Of Agriculture Quinazolinone-containing pharmaceutical compositions for prevention of neovascularization
IL114951A (en) * 1995-08-15 1999-08-17 Hadasit Med Res Service Quinazolinone-containing pharmaceutical compositions for prevention of neovascularization
CA2253362C (en) * 1996-08-30 2003-05-06 Arnon Nagler Intracoronary stents containing quinazolinone derivatives
US6028075A (en) 1997-02-11 2000-02-22 Pines; Mark Quinazolinone containing pharmaceutical compositions for prevention of neovascularization and for treating malignancies
US6562829B1 (en) 1997-05-23 2003-05-13 Hadasit Medical Research Services & Development Co., Ltd. Treatment of hepatic cirrhosis
JP2002515905A (ja) * 1997-05-23 2002-05-28 ハダシット・メディカル・リサーチ・サービセズ・アンド・ディベロップメント・カンパニー・リミテッド 肝硬変の治療
US6159488A (en) * 1997-08-14 2000-12-12 Agricultural Research Org. Ministry Of Agriculture (Gov.) Intracoronary stents containing quinazolinone derivatives
WO2000009070A2 (en) * 1998-08-13 2000-02-24 Hadasit Medical Research Services And Development Company Ltd. Inhibition of pathogenic processes related to tissue trauma
US7230000B1 (en) * 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
IL143366A0 (en) * 2001-05-24 2002-04-21 Harasit Medical Res Services & Treatment of renal fibrosis
US6753428B2 (en) * 2001-11-20 2004-06-22 Cytokinetics, Inc. Process for the racemization of chiral quinazolinones
IL147416A (en) * 2001-12-31 2008-11-26 Israel State Combined modalities for improved cancer treatment
CA2475879A1 (en) * 2002-02-15 2003-08-28 Cytokinetics, Inc. Synthesis of quinazolinones
IL148292A (en) * 2002-02-21 2008-08-07 Shai Yarkoni Stable preparations of lupoginone and other quinazolinone derivatives
AU2003270015A1 (en) 2002-05-09 2003-12-02 Cytokinetics, Inc. Compounds, compositions, and methods
WO2003094839A2 (en) * 2002-05-09 2003-11-20 Cytokinetics, Inc. Pyrimidinone compounds, compositions and methods
EP1513820A4 (en) * 2002-05-23 2006-09-13 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
AU2003236527A1 (en) * 2002-06-14 2003-12-31 Cytokinetics, Inc. Compounds, compositions, and methods
EP1537089A4 (en) * 2002-07-23 2008-04-16 Cytokinetics Inc CONNECTIONS, COMPOSITIONS AND PROCEDURES
EP1539180A4 (en) * 2002-08-21 2006-08-30 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
AU2003277079A1 (en) * 2002-09-30 2004-05-04 Cytokinetics, Inc. Compounds, compositions, and methods
WO2005041888A2 (en) * 2003-11-03 2005-05-12 Cytokinetics, Inc. Pyrimidin-4-one compounds, compositions and methods
JP2007510660A (ja) * 2003-11-07 2007-04-26 サイトキネティクス・インコーポレーテッド 化合物、組成物及び方法
US7439254B2 (en) * 2003-12-08 2008-10-21 Cytokinetics, Inc. Compounds, compositions, and methods
CN1304391C (zh) * 2004-02-06 2007-03-14 上海因诺生化科技有限公司 氢溴酸常山酮的制备方法
AU2006217453A1 (en) * 2005-02-23 2006-08-31 Collgard Biopharmaceuticals Ltd. Pharmaceutical compositions of the isolated D- enantiomer of the quinazolinone derivative halofuginone
WO2007120606A2 (en) * 2006-04-10 2007-10-25 President And Fellows Of Harvard College Methods for modulating formation and progression of cellulite
WO2008060621A2 (en) * 2006-11-17 2008-05-22 Abbott Laboratories Aminopyrrolidines as chemokine receptor antagonists
CA2711743C (en) 2007-01-21 2015-04-07 Agricultural Research Organization Quinazolinone derivatives for treating or preventing skeletal muscle fibrosis
US20090123389A1 (en) * 2007-08-15 2009-05-14 Malcolm Whitman Methods for modulating Th17 cell development in the treatment and prevention of cellulite
WO2009023267A2 (en) * 2007-08-15 2009-02-19 President And Fellows Of Harvard College Methods for modulating development and expansion of il-17 expressing cells
FR2922451A1 (fr) * 2007-10-23 2009-04-24 Windgan Trading Traitement des retrecissements de l'uretre
CA2737219C (en) * 2008-08-11 2017-02-28 Tracy Keller Halofuginone analogs for inhibition of trna synthetases and uses thereof
US8357692B2 (en) 2010-06-20 2013-01-22 Washington University Methods of treatment of bone degenerative diseases
AU2013207796B2 (en) 2012-01-13 2017-04-27 President And Fellows Of Harvard College Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions
US11708353B2 (en) 2018-06-08 2023-07-25 The General Hospital Corporation Inhibitors of prolyl-tRNA-synthetase
CN111233831A (zh) * 2020-03-18 2020-06-05 郑州市华农兽药研究院 常山铜琥珀酸单酯及其制备方法与用途
CN112409272B (zh) * 2020-11-26 2025-09-16 河北美荷药业有限公司 一种6-氯-7-溴-4（3h）-喹唑啉酮的制备方法和应用

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2703652A1 (de) * 1976-01-29 1977-08-04 Roussel Uclaf Neues chinazolinon und dessen salze, deren herstellungsverfahren und diese enthaltende pharmazeutische zusammensetzungen
FR2468368A1 (fr) * 1979-08-23 1981-05-08 Hoechst Ag Agent pour le traitement de theilerioses a base de quinazolinone
EP0027768A1 (fr) * 1979-10-23 1981-04-29 Roussel-Uclaf Nouvelles résines échangeuses d'ions du type acide, leur préparation, leur application comme médicaments et les compositions les renfermant
FR2467630A1 (fr) * 1979-10-23 1981-04-30 Roussel Uclaf Nouvelles resines echangeuses d'ions du type acide, leur procede de preparation et leur application comme medicament
EP0794780A4 (en) * 1994-12-22 1997-11-12 Davidson M Clifford PHARMACEUTICAL COMPOSITIONS CONTAINING QUINAZOLINONE AND METHODS OF USE THEREOF

Also Published As

Publication number Publication date
DE1545551A1 (de) 1969-10-16
IL23717A (en) 1971-01-28
US3320124A (en) 1967-05-16
BR6571429D0 (pt) 1973-08-14
DE1545551B2 (de) 1976-12-23
ES315612A1 (es) 1966-07-01
GB1087015A (en) 1967-10-11

Similar Documents

Publication Publication Date Title
FR1550956A (enExample)
AU4679664A (enExample)
BE627390A (enExample)
BE642437A (enExample)
BE432268A (enExample)
BE47396A (enExample)
BE483969A (enExample)
BE507097A (enExample)
BE518974A (enExample)
BE554195A (enExample)
BE564626A (enExample)
BE660794A (enExample)
BE584699A (enExample)
BE660624A (enExample)
BE660450A (enExample)
BE659403A (enExample)
BE659230A (enExample)
BE603534A (enExample)
BE658278A (enExample)
BE657921A (enExample)
BE657794A (enExample)
BE654277A (enExample)
BE610935A (enExample)
BE642974A (enExample)
BE642797A (enExample)

Legal Events

Date Code Title Description
CL Concession to grant licences